moatshark My

All holdings

Gilead Sciences

GILD

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
2
In their latest 13F (Q3 2026)
See who
Value held
$3.0bn
Combined value at quarter end
Last quarter
0 bought
1 sold or trimmed
Price at Q2 ’26 end
$126.34
-9.3% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

+22.2%Q3 ’24
+10.2%Q4 ’24
+21.3%Q1 ’25
-1.1%Q2 ’25
+0.1%Q3 ’25
+10.6%Q4 ’25
+13.5%Q1 ’26
-9.3%Q2 ’26
Q3 ’24: +22.2%; Q4 ’24: +10.2%; Q1 ’25: +21.3%; Q2 ’25: -1.1%; Q3 ’25: +0.1%; Q4 ’25: +10.6%; Q1 ’26: +13.5%; Q2 ’26: -9.3%

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

2Q4 ’23
2Q1 ’24
2Q2 ’24
2Q3 ’24
2Q4 ’24
1Q1 ’25
2Q2 ’25
2Q3 ’25
2Q4 ’25
2Q1 ’26
2Q2 ’26
0Q3 ’26
Q4 ’23: 2; Q1 ’24: 2; Q2 ’24: 2; Q3 ’24: 2; Q4 ’24: 2; Q1 ’25: 1; Q2 ’25: 2; Q3 ’25: 2; Q4 ’25: 2; Q1 ’26: 2; Q2 ’26: 2; Q3 ’26: 0

Counts the managers on this site whose 13F for that quarter includes Gilead Sciences.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Gilead Sciences
Dodge & Cox1.6%$3.0bn$3.0bnTrimmed -2.4%48 qtrs
Mairs & Power0.0%$287k$287kUnchanged5 qtrs

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works
From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Insider purchases and sales of Gilead Sciences
Bought or soldFiling
15 Oct 2026Dickinson Andrew DChief Financial Officer▼ Sold3,000$156.22$469kForm 4
1 Oct 2026O'Day Daniel PatrickChairman & CEO▼ Sold12,000$147.72$1.8mForm 4
1 Oct 2026O'Day Daniel PatrickChairman & CEO▼ Sold3,000$148.63$446kForm 4
15 Sep 2026Dickinson Andrew DChief Financial Officer▼ Sold3,000$145.29$436kForm 4
15 Sep 2026Mercier JohannaChief Comm & Corp Aff Officer▼ Sold1,600$143.69$230kForm 4
15 Sep 2026Mercier JohannaChief Comm & Corp Aff Officer▼ Sold800$144.46$116kForm 4
15 Sep 2026Mercier JohannaChief Comm & Corp Aff Officer▼ Sold600$145.29$87kForm 4
1 Sep 2026O'Day Daniel PatrickChairman & CEO▼ Sold7,992$148.36$1.2mForm 4
1 Sep 2026O'Day Daniel PatrickChairman & CEO▼ Sold5,408$149.38$808kForm 4
1 Sep 2026O'Day Daniel PatrickChairman & CEO▼ Sold1,600$147.51$236kForm 4
26 Aug 2026Welters AnthonyDirector▼ Sold6,880$148.82$1.0mForm 4
26 Aug 2026Welters AnthonyDirector▼ Sold4,600$148.82$685kForm 4
26 Aug 2026Welters AnthonyDirector▼ Sold3,402$148.24$504kForm 4
26 Aug 2026Welters AnthonyDirector▼ Sold3,118$148.31$462kForm 4
20 Aug 2026Bluestone JeffreyDirector▼ Sold1,816$144.92$263kForm 4
20 Aug 2026Bluestone JeffreyDirector▼ Sold1,658$145.73$242kForm 4
20 Aug 2026Bluestone JeffreyDirector▼ Sold1,165$143.75$167kForm 4
20 Aug 2026Bluestone JeffreyDirector▼ Sold335$146.26$49kForm 4
20 Aug 2026Bluestone JeffreyDirector▼ Sold26$146.36$4kForm 4
17 Aug 2026Mercier JohannaChief Comm & Corp Aff Officer▼ Sold16,530$137.37$2.3mForm 4

About the company

Sector
Health care · Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Financial year ends
31 December
Shares outstanding
1.24bn at 31 Jul 2026
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

$11bn2013
$33bn2015
$26bn2017
$22bn2019
$27bn2021
$27bn2023
$29bn2025
2013: $11bn; 2014: $25bn; 2015: $33bn; 2016: $30bn; 2017: $26bn; 2018: $22bn; 2019: $22bn; 2020: $25bn; 2021: $27bn; 2022: $27bn; 2023: $27bn; 2024: $29bn; 2025: $29bn
Gilead Sciences revenue and net income by year
YearRevenueNet income
2025$29bn$8.5bn
2024$29bn$480m
2023$27bn$5.7bn
2022$27bn$4.6bn
2021$27bn$6.2bn
2020$25bn$123m
2019$22bn$5.4bn
2018$22bn$5.5bn
2017$26bn$4.6bn
2016$30bn$14bn
2015$33bn$18bn
2014$25bn$12bn
2013$11bn$3.1bn

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.